CLL | Tumor

What's Included in the Diagnosis and Staging of CLL?

February 21st 2020

Nathan's Story: Receiving a Diagnosis of CLL

February 21st 2020

The Indolent Nature of Chronic Lymphocytic Leukemia

February 21st 2020

Chronic Lymphocytic Leukemia: Risks and Complications

February 21st 2020

Background on Chronic Lymphocytic Leukemia and Treatment

February 21st 2020

The Use of Immunotherapy in Blood Cancer Treatment

February 7th 2020

Exciting Treatment Options Being Developed in Multiple Myeloma

February 7th 2020

Genetic Sequencing in Chronic Lymphocytic Leukemia

February 7th 2020

The Basics of Mantle Cell Lymphoma

February 7th 2020

Joining a Clinical Trial

February 7th 2020

Fixed-Duration Regimen More Cost-Effective Than Treat-Until-Progression Therapies in CLL

February 7th 2020

The novel drug pairing of Venclexta and Gazyva, used for a fixed 12 months, is cost-effective compared with regimens that must be taken until disease progresses, a study finds.

Choosing the Best Therapy for Patients with Chronic Lymphocytic Leukemia

January 17th 2020

With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.

Psychosocial Intervention for Caregivers May Improve Quality of Life

January 16th 2020

A brief, multimodal psychosocial intervention for caregivers of patients undergoing hematopoietic stem cell transplantation could improve their quality of life, caregiving burden and anxiety and depression symptoms.

Information at Your Fingertips

January 16th 2020

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with the associate director of the Information Resource Center at the Leukemia and Lymphoma Society on support groups and other recourses available for those affected by blood cancer.

Limiting Treatment Duration Improves Cost Effectiveness in CLL

January 5th 2020

Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.

Clinical Trial Participants May Fare Better Than Medicare Beneficiaries Treated with Zydelig

January 4th 2020

Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.

A Look Back at the Top 10 CURE Stories of 2019

December 30th 2019

As 2019 comes to a close, take a read through CURE®’s top stories of the year.

CURE's Top 10 Podcasts of 2019

December 27th 2019

Take a look back at the top 10 podcasts of 2019 – and be sure to subscribe so you don’t miss an episode in 2020.

Don't Ignore Your Wake-Up Call

December 11th 2019

When one woman experienced symptoms of chronic lymphocytic leukemia, people blamed her nerves and told her to rest. Instead, she listened to her body.

Ibrutinib and Rituximab Improve Progression-Free Survival for Patients with CLL

December 10th 2019

Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

What Patients With CLL/SLL Should Know About the FDA's Approval of Calquence

November 28th 2019

The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.

FDA Approves Calquence for Leukemia and Lymphoma Subsets

November 21st 2019

In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

A Fortunate Turn of Events in Chronic Lymphocytic Leukemia

September 17th 2019

In what was once an incurable cancer — chronic lymphocytic leukemia — scientists are seeing remissions that could last for decades.

CURE's Top 5 Stories: July 2019

August 1st 2019

Here are the top 5 CURE stories for July 2019.

FDA Approves Biosimilar Ruxience: Here's What You Need to Know

July 24th 2019

With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.

FDA Approves Rituxan Biosimilar to Treat Blood Cancers

July 23rd 2019

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Be Your Own Advocate

June 18th 2019

Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.

Venclexta Plus Gazyva Reduces Disease Progression by 65% in Patients with CLL

June 6th 2019

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.

Combination Therapies Offer Newer Options for CLL Treatment

May 31st 2019

Patients with chronic lymphocytic leukemia have newer options that include targeted therapy combinations and CAR-T cell therapy.

FDA Approves Venclexta-Gazyva Combo as Frontline Treatment for CLL/SLL

May 15th 2019

The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.